Thomas Lohnes/Getty Images News
BioNTech (NASDAQ:BNTX) ADRs added ~2% in the premarket on Monday after the German vaccine maker exceeded Street forecasts with its Q2 2025 financials, thanks mainly to an over two-fold rise in its revenue.
The maker of the Pfizer (PFE)-partnered Comirnaty COVID-19 vaccine reported €1.60 ($1.85) of loss per share on €260.8M ($302.1) of revenue for Q2, compared to €2.28 of loss and €150.93M of revenue projected by analysts, according to FactSet data.
BioNTech’s (NASDAQ:BNTX) topline indicated ~103% YoY growth in Q2, and its H1 revenue reached €443.6M, implying ~40% YoY growth, with increases attributed to higher revenues generated from the company’s COVID vaccine partnership with Pfizer (PFE).
Meanwhile, BNTX’s net loss dropped ~52% YoY to €386.6M in Q2 as R&D expenses fell ~13% YoY to €509.1M, mainly due to pipeline reprioritization efforts, and the company’s SG&A expenses narrowed ~25% YoY to €137.4M, thanks mainly to a decline in external services.
Looking ahead, BioNTech (NASDAQ:BNTX) reaffirmed its revenue outlook of €1.7B – €2.2B for 2025 compared to €1.98B in FactSet Consensus.